Improvement of thiol groups and total antioxidant capacity in patients with non-alcoholic fatty liver after treatment with pioglitazone

References

• Abenavoli, L., et al., 2017. Effect of Mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study. Nutrients, 9 (8), 870.
   Web of Science ®Google Scholar
• Ahn, H.Y., et al., 2018. Effects of pioglitazone on nonalcoholic fatty liver disease in the absence of constitutive androstane receptor expression. PPAR research, 2018, 9568269.
   PubMed Web of Science ®Google Scholar
• Ashraf, N.U. and Sheikh, T.A., 2015. Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free radical biology, 49 (12), 1405–1418.
   Google Scholar
• Başkol, M., Dolbun Seçkin, K., and Başkol, G., 2014. Advanced oxidation protein products, total thiol levels and total oxidant/antioxidant status in patients with nash. Turkish journal of gastroenterology, 25 (Suppl 1), 32–37.
   PubMedGoogle Scholar
• Benedict, M. and Zhang, X., 2017. Non-alcoholic fatty liver disease: an expanded review. World journal of hepatology, 9 (16), 715–732.
   PubMed Web of Science ®Google Scholar
• Borrelli, A., et al., 2018. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches. Redox biology, 15, 467–479.
   PubMed Web of Science ®Google Scholar
• Cobbina, E. and Akhlaghi, F., 2017. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug metabolism reviews, 49 (2), 197–211.
   PubMed Web of Science ®Google Scholar
• de Alwis, N.M., Anstee, Q.M., and Day, C.P., 2016. How to diagnose nonalcoholic fatty liver disease. Digestive diseases (Basel, Switzerland), 34 (Suppl 1), 19–26.
   PubMedGoogle Scholar
• Feng, R., et al., 2017. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case–control study. Lipids in health and disease, 16 (1), 165.
   PubMedGoogle Scholar
• Gambino, R., et al., 2016. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. International journal of molecular sciences, 17 (4), 479.
   PubMed Web of Science ®Google Scholar
• Gao, B. and Tsukamoto, H., 2016. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology, 150 (8), 1704–1709.
   PubMed Web of Science ®Google Scholar
• Gorden, D.L., et al., 2015. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Journal of lipid research, 56 (3), 722–736.
   PubMed Web of Science ®Google Scholar
• Hussain, T., et al., 2016. Oxidative stress and inflammation: what polyphenols can do for us? Oxidative medicine and cellular longevity, 2016, 7432797.
   PubMed Web of Science ®Google Scholar
• Koruk, M., et al., 2004. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Annals of clinical and laboratory science, 34 (1), 57–62.
   PubMed Web of Science ®Google Scholar
• Kumar, A., et al., 2013. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. Journal of clinical and experimental hepatology, 3 (1), 12–18.
   PubMedGoogle Scholar
• Machado, M.V. and Cortez-Pinto, H., 2014. Non-alcoholic fatty liver disease: what the clinician needs to know. World journal of gastroenterology, 20 (36), 12956–12980.
   PubMed Web of Science ®Google Scholar
• Manco, M., 2017. Insulin resistance and NAFLD: a dangerous liaison beyond the genetics. Children, 4 (8), 74.
   Google Scholar
• Milić, S., Lulić, D., and Štimac, D., 2014. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World journal of gastroenterology, 20 (28), 9330–9337.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri, B.A., 2017. Non-alcoholic fatty liver disease. BMC medicine, 15 (1), 45.
   PubMed Web of Science ®Google Scholar
• Ore, A. and Akinloye, O.A., 2019. Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. Medicina, 55 (2), 26.
   Google Scholar
• Papatheodoridi, M. and Cholongitas, E., 2018. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): current concepts. Current pharmaceutical design, 24 (38), 4574–4586.
   PubMed Web of Science ®Google Scholar
• Samy, W. and Hassanian, M.A., 2011. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab journal of gastroenterology, 12 (2), 80–85.
   PubMedGoogle Scholar
• Singh, S., Osna, N.A., and Kharbanda, K.K., 2017. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World journal of gastroenterology, 23 (36), 6549–6570.
   PubMed Web of Science ®Google Scholar